TGF beta receptor antagonist + ASGR1 antibody conjugate (Silverback Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTGF beta receptor antagonist + ASGR1 antibody conjugate (Silverback Therapeutics)
Drug Alias NameASGR1-TGFbetaR
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTransforming growth factor beta receptors antagonistsAsialoglycoprotein receptor 1 modulators
TargetsAsialoglycoprotein receptor 1Transforming growth factor beta receptors
Therapy Area/IndicationsLiver Cirrhosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSilverback Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSilverback Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsLiver Cirrhosis

Other Information

ATC CodeN/A
Related LinksN/A